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Abstract
Purpose. 4D-CT is routine imaging for lung cancer patients treatedwith stereotactic body
radiotherapy. No studies have investigated optimal 4Dphase selection for radiomics.We aim to
determine howphase data should be used to identify prognostic biomarkers for distant failure, and
test whether stability assessment is required. A phase selection approachwill be developed to aid
studies with different 4Dprotocols and account for patient differences.Methods. 186 features were
extracted from the tumour and peritumour on all phases for 258 patients. Feature values were selected
fromphase features using fourmethods: (A)mean across phases, (B)median across phases, (C) 50%
phase, and (D) themost stable phase (closest in value to twoneighbours), coined personalised
selection. Four levels of stability assessmentwere also analysed, with inclusion of: (1) all features,
(2) stable features across all phases, (3) stable features across phase and neighbour phases, and (4)
features averaged over neighbour phases. Clinical-radiomicsmodels were built for twelve combina-
tions of feature type and assessmentmethod.Model performancewas assessed by concordance index
(c-index) and fraction of new information from radiomic features.Results. Themost stable phase
spanned thewhole range but wasmost often near exhale. All radiomic signatures provided new
information for distant failure prediction. The personalisedmodel had the highest c-index (0.77), and
58%of new informationwas provided by radiomic features when no stability assessment was
performed.Conclusion. Themost stable phase varies per-patient and selecting this improvesmodel
performance compared to standardmethods.We advise the singlemost stable phase should be
determined byminimising feature differences to neighbour phases. Stability assessment over all
phases decreases performance by excessively removing features. Instead, averaging of neighbour
phases should be usedwhen stability is of concern. Themodels suggest that higher peritumoural
intensity predicts distant failure.
1. Introduction
Stereotactic ablative radiotherapy (SABR) offers improved disease control and reduced toxicity compared to
conventional radiotherapy for patients with early stage non-small cell lung cancer (NSCLC) (Nyman et al 2016).
Despite success, around 20%of patients will experience distant failure withinfive years, and prognostic factors
are notwell developed (Senthi et al 2012, Loganadane et al 2016). Imaging biomarkers would be beneficial in this
area for personalised treatment, or stratification in clinical trials, for example, to select patients that would
benefit from surgery rather than SABR.
Radiomics, the extraction and analysis of quantitative features frommedical images, could aid prognosis
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approximately 100 patients or less (Huynh et al 2016, 2017, Li et al 2017,Oikonomou et al 2018, Lafata et al
2019), and few analyse four-dimensional computed tomography (4D-CT) data, which is used in lung cancer
radiotherapy planning. As small tumours can exhibit largemotion during respiration (Henry et al 2012),
radiomic studies of free-breathing CT (FB-CT) are affected bymotion variability (Fave et al 2015,Du et al 2019).
The inclusion of 4D-CT could help overcome such issues, as each phase in the respiratory cycle displays a
snapshot in time.With typically ten phases available (0%–90%), and composite reconstructions created for
planning (such as the average intensity projection (AIP)), uncertainty remains in how to use this data in radiomic
studies.
The simplest choice is theAIP reconstruction and tumour features (TFs) fromAIP have out-performed
FB-CT features for prediction of distant failure (Huynh et al 2017). However, the AIP represents average patient
anatomy resulting in a blurred representation of amoving tumour. Instead, a single 4Dphase is advised
(Fornacon-Wood et al 2020), and end-exhale phase (50%) has out-performed both FB-CT andAIP for
prediction of tumour histology (Lafata et al 2018). Commonly, AIP and end-exhale aremixed in analysis
dependent on availability (Li et al 2017), despite the significant difference in feature values from each (Fave et al
2015). A single phase is useful to avoid a blurred representation of anatomy; however, the influence that different
phase selection algorithms have on prognosticmodels is unknown.
End-exhale phase is often assumed themost stable for all patients (George et al 2006), but, there can be
motion artifacts on any phase due to erratic breathing and heartmotion (Fredberg Persson et al 2011). In
addition, it is often assumed 50% is end-exhale, but this depends on howdata is sorted. For phase angle sorting
frompeak inhale (standard in Philips scanners) the phase corresponding to end-exhale is not consistent across
patients, as time spent in exhalation varies. Furthermore, the inspiration phase has been used in analysis without
comparison (Franceschini et al 2020). A single pre-determined phase for all patients is potentially undesirable
due to difference in data-binning implemented across institutions and individual patient differences. Instead, a
phase selection tool to informwhich phase ismost suitable for each individual patient would account for
different 4Dprotocols, and randompatient and organmotion. Such an approachwould aidmulti-institutional
studies.
So far, rather than investigating the prognostic value of different phase features, studies have sought features
that agree across phases to reduce noise. Larue et al considered all phases (Larue et al 2017), whereas, Tanaka et al
assessed phases neighbouring end-exhale (Tanaka et al 2019). Stability assessment will remove features
descriptive of anatomical details that are sensitive to distortion (Larue et al 2017). This is of concern for distant
failure prediction, as details from the tumour periphery can be linked to prognosis (Shimada et al 2010, Kadota
et al 2015). Averaging feature values is another formof noise reduction (Zwanenburg et al 2019a), but the
influence this has on prediction is unknown.
In this study, we aim to offer a data-driven approach to phase selection and study how to combine 4Dphase
information to offer best prognostic value. To do this, we compare fourmethods of obtaining a single feature set
fromphase feature values: (A)mean across all phases, (B)median across all phases, (C) 50%phase, or (D)
selection ofmost stable phase for each patient based on similarity to neighbouring phases, coined the
personalised approach. To fully analyse the 4D radiomics framework andmake recommendations, we also
comparemethods of stability assessment by including: (1) all features, (2) features stable across 10 phases, (3)
features stable across neighbour phases, and (4) all features but averaged across neighbour phases. 12models will
be created from suitable combinations of feature type and assessmentmethod. This analysis will be performed in
the clinical setting of distant failure prediction in early-stageNSCLC, as this is an area of unmet need that would
benefit from an imaging biomarker to guide optimalmanagement.
2.Material andmethods
2.1.Data collection
273 stage I and IIaNSCLCpatients (confirmed histologically or suspected based on radiology)were identified
frompatients treatedwith SABR for primary lung cancer during 2011–2017, in a single centre. Image, planning,
and follow-up datawere available. All patients had amotion-adapted gross tumour volume (iGTV) contoured in
clinical practice, andwere treatedwith 54Gy in 3 fractions, or 60Gy in 5 or 8 fractions.
4D-CT scanswere acquired pre-treatment with the imaging protocol described in supplementarymaterial
(SM), section 1 (available online at stacks.iop.org/PMB/66/115012/mmedia) . 4D datawas sorted into ten
respiratory bins of equal time 0%–90%,where 0%phase represents peak inhale. All scanswere reconstructed
with slice thickness 3mm, andmajority with pixel size 1.17 mm (range: 0.98–1.37 mm). Patients withmissing
image or treatment data, or complex treatment cases (i.e.more than one lesion)were removed from further
analysis. Approval was granted to collect and analyse this patient data (REC reference: 17/NW/0060).
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2.2. Patient follow-up
In agreementwithUK guidelines (SABRUKConsortium2019), patients underwent clinical follow-up four to
sixweeks after treatment. Patients were then followed-up every threemonths for the first year, and sixmonthly
thereafter. A FB-CTwas performed at the discretion of each clinician, with an 18F-FDGpositron emission
tomography (PET) scan and/or biopsy recommendedwhen recurrence was suspected. For this study, follow-up
datawas collected retrospectively by a clinical team.Distant failure was defined as recurrence in an uninvolved
lobe, contralateral lung, or any other extra-thoracic location. Time to distant failure was recorded from start of
radiotherapy treatment to date offirst scan that shown progression. If therewas no recurrence, patients were
censored atmost recent follow-up.
Clinical variables available were tumour lobe location, T stage, age, sex, ECOGperformance status (a grading
0–5 based on functional ability), ACE-27 comorbidity score (a gradingmild–severe based on presence and
severity of pre-existingmedical conditions), and histological sub-type. Only patients inwhom the clinical
variable data collectionwas complete were considered in analysis against outcome.
2.3. Region-of-interest segmentation
An in-house, validatedmethodwas implemented to generate aGTVon a reference phase (50%) from the iGTV
for all patients (Davey et al 2020a). Briefly, local-rigid registrationwas used to obtain the translation set required
tomatch the tumour position on each phase to the reference i.e. estimating tumourmotion. The iGTV
represents the volumemapped by theGTVover themotion trajectory, so from the iGTV and estimatedmotion
theGTV can be derived (Step 2, figure 1). TheGTVwasmapped into the tumour position on every phase using
the registration translation andmaskswere sampled (Step 3, figure 1).
Patients were excluded from analysis if classed as failed registration on visual assessment. Tumourmotion
amplitudewas recorded by combining the difference inmaximumandminimumpositions from translation in
all directions as a vector. Tumour volumewas sampled from the 50%phasemask. Patients were excluded from
analysis if tumour volumewas below 64 voxels. This limit has been implemented in radiomics software (Nioche
et al 2018), described as the volume belowwhich texture features aremeaningless.
A peritumoral borderwas sampled on every phasewhichwas defined as a region 3mm inside and outside the
GTV contour, following a published definition (Dou et al 2018). A correction algorithmwas developed (SM,
section 2) and applied to each phase to remove any high-density normal tissue (i.e. diaphragm, chest wall, or
bone). After correction, only voxels which exist fully inside the corrected peritumoural border were included in
analysis. The number of included voxelsmay differ across phases due tomotion relative to chest wall and
diaphragmposition, or a smaller than voxel sizemotion amplitude. This would be the only reason for a change
in volume across phases, as we assume there is no deformation of the tumour over the respiratory cycle. This
assumption is based on biomechanics—as the tumour is a relatively rigidmass embedded inmuch softer lung
tissue.
2.4. Feature extraction
Anopen source software, Pyradiomics version 2.2.0, was used in Python 3.6.9 for feature extraction (van
Griethuysen et al 2017).Majority of features in this software are compliant with the Image Biomarker
Standardisation Initiative (Zwanenburg et al 2019b, Fornacon-Wood et al 2020). 93 first order and texture
features available were extractedwith default settings, which comprised of feature groups: first order,
symmetrical grey level co-occurrencematrix (GLCM), grey level size zonematrix, grey level run lengthmatrix,
neighbouring grey tone differencematrix, and grey level dependencematrix (GLDM). Features were extracted
fromboth an original and filtered image, using a Laplacian ofGaussian (LoG)filter with sigma,σ, as 1.5 mm, to
look atmedium edge textures (Ganeshan et al 2010). Features were extracted fromboth the tumour and
Figure 1.The steps implemented to obtain the regions-of-interest. Step 1 is the clinical iGTV. Step 2 shows theGTV contour generated
on the 50%phase using an in-housemethod. Step 3 shows the contour sampled as amask on phases, with 0% and 50% shown for an
example, and Step 4 shows the peritumoural border sampled as amask on the same phases. Step 5 shows the peritumoural border
following correction for high-density normal tissue.
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peritumoural regions-of-interest (ROIs), labelled TFs and peritumoural features (PFs) respectively, resulting in
372 features per phase.
Feature extractionwas performed on the original voxel spacingwithout resampling, as almost 80%of
images are the same pixel spacing, and all approximately 1mmwith slice thickness 3 mm.Although isotropic
resampling has been recommended, the best practice for implementation is an area of active researchwith no
favoured approach (VanTimmeren et al 2020). Afixed bin size approachwas implementedwith bin-size of 25
HounsfieldUnits (HU), the default setting in Pyradiomics. The lower bound on this data was−1024HU from
thewhole CT range, but varied for each patient asminimumvalue in theROI. A re-segmentation lower bound
was not defined as presence of air is potentially informative.
2.5. Creation of single feature set
Fourmethods (A)–(D)were implemented to produce single feature sets:
(A) mean feature values across all phases,
(B) median feature values across all phases,
(C) feature values from50%phase,
(D) personalised approach allowing themost stable phase to be selected for each patient.
Themost stable phase was defined as the phase withminimum sumof difference in radiomic feature value
compared to its two neighbour phases. Initially, for each patient n, each featurewas considered separately. For
each feature value (XF) extracted from each phase (Ph) in turn, the sumof the difference in value compared to the
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calculated in a cyclic way so that when Ph is 0%, Ph− 1 is 90%, andPh is 10%.
The phase which results inminimumΔX across comparisons ismost stable for each patient-feature pair.
Themost commonphase occurring across all radiomic features for each patient was selected as themost stable
phase, and the corresponding feature valueswere stored for analysis. Thefinal feature sets were used
independently in the full analysis process displayed infigure 2.
2.6. Stability assessment
To assess whether stability assessment affects prognostic performance we analysed four approaches:
Figure 2. Flow diagramof radiomics analysis. A–D refer to different feature types:mean,median, 50%, and personalised respectively.
Boxes 1–4 indicate the different stability assessmentmethods (all features, unstable features across 10 phases removed, unstable
features across neighbouring phases removed, and all features averaged across neighbour phases) implemented on the corresponding
feature type. The section highlightedwith a yellowbackground includes an internal validation process (cross-validation and bootstrap
resampling).
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(1) All features included (None),
(2) Enforce stability across ten phases (Stability (10)),
(3) Enforce stability across neighbour phases (Stability (3)),
(4) Averaging across neighbour phases (Averaging (3)).
A two-waymixed effects intraclass correlation coefficient was used to assess absolute agreement of feature
values across phases compared to a single phase, ICC(A,1)—implemented across all phases formethod 2, and
three phases formethod 3. A lower bound of the 95% confidence interval (CI) greater than or equal to 0.85was
defined as stable, which represents good-to-excellent agreement (Koo and Li 2016), and compareswith reported
thresholds (Larue et al 2017, Tanaka et al 2019). The suitability of this thresholdwas investigated by exploring the
relationship between number of stable features for different threshold levels, and influence of tumourmotion
and volume on stability was considered.
As shown infigure 2, assessmentmethods 1 and 2 apply to all feature sets (A–D), but, 3 and 4 involve
neighbour phases and are only appropriate for single phase cases (C andD). For averaging (method 4), themean
of neighbour phases is stored for analysis (i.e. if 70% ismost stable, result is themean of 60%, 70%, and 80%).
Overall, 12models are created, summarised in table 1.
2.7. Feature selection andmodel building
2.7.1. Unsupervised feature selection
For each feature type-assessment combination, correlationwith tumour volumewas investigatedwith
Spearman rank correlation coefficient (ρ), and features with ρ above 0.5were removed. Next, TFs and PFswere
investigated independently for redundancy (linear correlation to other features)using Pearson correlation
coefficient. A threshold of greater than 0.5 in correlation coefficient highlighted correlated pairs, and the feature
in the correlated pair with the largest average correlation to all other features was removed. All features were
standardised tomean zero and unit variance, performed prior to cross-validation as the selected feature selection
techniques are not influenced by normalisation.
2.7.2. Supervised feature selection
Three supervised feature selection algorithmswere tested independently. Themethods implemented selected
features that: (1) are significantly associatedwith outcome in a univariable Cox regression (p<0.05), (2)
significantly improve amultivariable Cox regression of clinical variables in a likelihood-ratio (LR) test
(p<0.05), and (3) have a positive contribution based onminimum redundancymaximum relevance (MRMR)
ranking (De Jay et al 2013). Each techniquewas implemented independently over 200 samples created from40
five-fold stratified cross-validation (SCV)with event-matching.
Table 1.The radiomicmodels studiedwhich are formed from a suitable combination of amethod to extract a single feature set fromphase




• Unstable across 10 phases removed
• Unstable across neighbour phases removed
• Average features across neighbour phases
50%phase
• All features
• Unstable across 10 phases removed
• Unstable across neighbour phases removed
• Average features across neighbour phases
Mean across phases
• All features
• Unstable across 10 phases removed
Median across phases
• All features
• Unstable across 10 phases removed
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In each training run, selected features are combinedwith clinical variables to form a clinical-radiomics Cox
model, whichwas appliedwithout change to the test data. The concordance index (c-index)was calculated for
both training and testmodels with themedian and 95%CI across SCV runs recorded.
The feature selection technique thatmaximised performance whilstmaintaining a balance between training
and test data was selected. To implement, we calculated a performance ranking from themedian c-index across
all clinical-radiomicmodels for both the training (Ctrain) and test (Ctest) data
= - -Performance ranking C C C 2test test train∣ ∣ ( )
which is often used for hyper-parametrisation (RabascoMeneghetti et al 2021).
For the chosenmethod, the selected features from each training runwere recorded and ranked by
occurrence. The radiomics signature for each feature type-assessment combinationwas formed from the top
ranked features, with the number of features determined by themedian signature size across all SCV runs.
2.7.3.Model building
Based on cross-validation results, a clinicalmodel and 12 clinical-radiomicsmodels were built using the
complete dataset. For each clinical-radiomicsmodel (CR), we calculated the adequacy index of the baseline
















where LR is the likelihood ratio test c .2 Thismodel performance comparisonmetric is recommended byHarrell,
as difference in c-index (although common for radiomics studies Lambin et al 2017) is a low-powermetric for
interpreting the added value of radiomic features in a clinicalmodel (Harrell 2015). The fraction of new
information is the proportion of explainable variation in outcome that is provided by the radiomics signature.
The prognostic features were studied for interpretation.
Table 2.Patient demographics table for 258 patients. Total Number column records the number of patients with complete data for each
variable, also expressed as a percentage of the total number of patients in the dataset. Tumour volume represents the generatedGTVvolume
on 50%phase.Missing category in histological subtype includes thosewith radiological diagnosis. ECOG: EasternCooperativeOncology
Group. ACE-27: Adult Comorbidity Evaluation 27.
Variable Categories Number Total number
Sex Male 133 258 (100%)
Female 125
Age Median (range) 76 (45–93) 258 (100%)









Tumour volume (cm3) Median (Range) 4.02 (0.31–33.8) 258 (100%)









Histological subtype Adenocarcinoma,NOS 47 116 (45%)




Tumourmotion amplitude (mm) Median (range) 5.48 (0–34.3) 258 (100%)
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For comparison to radiomics literature, we also calculated themedian and 95%CI of the c-index for each
model across 500 bootstrap resamples. Following Steyerberg (2009) andHarrell (2015), each bootstrapmodel




Six patients were excluded prior to ROI segmentation: three had at least one phasemissing, two had contours
missing, and one hadmultiple lesions at treatment. Seven patients were excluded due to poor registration on
visual assessment, and two for notmeeting the volume threshold.Median follow-up time for all 258 remaining
patients was 18months (95%CI 15–20months), and 44 patients experienced distant failure.
The patient demographics are shown in table 2, with the level ofmissing data reported.Histological subtype
data was limited,many patients were diagnosed radiologically as poor health precluded a biopsy. Assessment of
comorbidity scorewas limited due to incomplete reporting in the electronic patient record. Consequently,
comorbidity score and histological subtypewere not included in themultivariable analysis, as the exclusionwas
not thought to impact comparison of radiomicmodels. In analysis of lobe location, ‘middle’was combinedwith
‘upper’ for ease of comparison. ‘ECOG0’was also combinedwith ‘ECOG1’ due to the sparse data in the lowest
performance status group.
All stages of data exclusion are shown infigure 3. The 258 patients recorded in table 2were considered
throughout thefirst stage, however, 203with complete informationwere used for feature selection andmodel-
building of which 37 experienced distant failure.
Figure 3. Flow diagram to demonstrate steps implemented to arrive at data available for analysis against outcome.N represents the
number of patients remaining, whilst n represents those removed.
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3.2. Feature extraction and creation of feature sets
Aswe did not consider tumour deformation, small changes in tumour volume across phases result from small
changes in border voxel inclusion. For 68%of patients the tumour volumewas the same across all phases,
overall, themean difference was 0.09 cm3with range 0–1.61 cm3. Theminimum intensity value differed across
patients (SM, section 3).
The following feature sets were evaluated:mean,median, 50%, and personalised. The personalised approach
selects themost stable phase for each patient individually. Formost patients, themost stable phasewas close to
exhale, with 50% selected for 33%.However, therewas not one suitable phase for all patients as the full range of
phaseswere selected (figure 4(A)). Personalised phase selection successfully reduced the chance of using a phase
with an artifact in radiomics analysis (figure 4(B)).
Phases were chosen based onmajority of features, but, themost stable phase differed per feature, and the
selectionwill depend onwhat features are used in analysis.
3.3. Stability assessment
Exploring all features, 34%of TFs and 40%of PFswere unstable across ten 4Dphases, with an overlap of 41
features common across the twoROIs. 11%of TF and PFwere unstable across the neighbour phases to 50%and
personalised. This classification is largely dependent on chosen ICC threshold, and data studied, as variability is
influenced by tumourmotion and tumour volume (SM, section 4).
3.4. Unsupervised feature selection
The percentage of features remaining at each stage of unsupervised feature selection (stability assessment,
volume correlation, and redundancy) are shown in table 3. A similar proportion of features were removed
regardless of feature type and assessmentmethod, with less than 6% remaining in all cases. Themost features
remained after averaging across neighbour phases, and typically for the personalised or 50%phase across each
method.
3.5. Supervised feature selection
Supervised feature selection influencedmodel performance; however, the top ranking of feature type-
assessment combinationswas consistent (SM,figure 4). Therewas typically a larger difference across 4D
frameworks than feature selection techniques. Themedian performance ranking (equation (2))was 0.42 for
univariable, 0.4 formultivariable, and 0.43 andMRMR, and similar signature lengths were derived across
techniques (SM,figure 5).
Following implementation ofMRMR (highest ranking), themedian signature size across 4D frameworks
ranged from2 to 4 features. Themedian size was used to select the top ranked features, the frequency of
occurrence of which is displayed infigure 5. Stability (10) assessment leads to a completely different set of
features selected compared to no assessment, however, there are similarities across other techniques.
3.6. Prognosticmodel results
The c-index and fraction of new information for thefinal clinical-radiomicsmodels are displayed infigure 6.
The baseline clinicalmodel is reported in SM, table 3, with tumour volume, tumour lobe location, and biological
sex as significant predictors of distant failure.
Figure 4. (A) Frequency bar chart of themost stable phase selected for each patient. Exhale phases aremost often selected but the full
range of phases are chosen. (B)Patient example of 50%versus personalised selection. 50%phasewas not suitable for this patient due
to presence of a potential artifact (red arrow)which influenced the tumour appearance (tumour outlinedwith lime contour).
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All radiomicmodels outperform the clinicalmodel, with radiomic features offering new information to
distant failure prediction. The best performingmodel used the personalised phase with no additional stability
assessment. For both no assessment and averaging across neighbouring phases in the personalised case, the
radiomics signature has a greater than 0.5 fraction of new information i.e. a greater than 50%proportion in the
explainable variation is provided by the radiomics signature. Discarding unstable features over all ten phases has
a large negative impact onmodel performance (<20%new information).
For eachmodel, different features were included in the radiomics signature that have varying prognostic
value. Infigure 7, themultivariable hazard ratio and significance for features included in the best performing
models are displayed i.e. single-phase features with no assessment, or assessment performed over neighbouring
phases. Other results are included in SM, section 7 for completeness.
Table 3.The percentage of features (N%) remaining after each
stage of feature selection for the different feature type and
assessment combinations. Each column represents a stage of
feature selection: stability assessment, volume correlation, and
correlation to other features (redundancy). Averaging (3) and
Stability (3) refer to assessmentmethods including the
neighbouring phases (i.e. 3 phases in total), and Stability (10)
refers to all phase assessment.
Stage of unsupervised feature selection
Stability Volume Redundancy
None
Personalised 100 54.8 5.4
50 100 56.2 5.1
Mean 100 53.8 4.8
Median 100 54.0 5.1
Stability (10)
Personalised 62.6 30.4 2.7
50 62.6 31.2 3.0
Mean 62.6 29.0 2.4
Median 62.6 29.3 2.7
Stability (3)
Personalised 89.2 50.5 4.0
50 89.0 52.2 4.8
Averaging (3)
Personalised 100 53.2 5.6
50 100 53.8 5.4
%of features remaining at each stage.
Figure 5.Bar chart to represent frequency of feature selection ranking across cross-validation runs for different feature type (colours),
and assessmentmethod (panels) usingMRMR feature selection. Frequency represents the percentage of features selected across SCV
runs.
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Across all cases the personalisedmodel containsmore features that are significant after adjusting for clinical
variables (p<0.05). For no stability assessment, the PFsGLCMCorrelation calculated on the LoG image and
GLDM large dependence low grey level emphasis (LDLGLE) are included in the 50%and personalisedmodel,
but only significant in the personalised case. These features remain significant in the personalisedmodel after
averaging is performed, but, GLCMcorrelation does not remain significant after stability (3) assessment is
implemented. For Stability (3), GLDMLDLGLE is replacedwithGLDMsmall dependence high grey level
emphasis, which are correlated (ρ=−0.52).
TFGLCMmaximumprobability is statistically significant in the 50%,mean, andmedianmodel with no
stability assessment (SM, section 7). This feature is highly correlated to the TFGLDMDependence Variance
which is significant in the personalisedmodel (ρ= 0.89).
4.Discussion
In this study, we have a developed amethod to select themost stable 4D-CTphase for radiomics analysis. The
method improvedmodel performance for distant failure prediction compared to the 50%phasewhich is often
assumedmost stable (Lafata et al 2018), or averaging ten phase feature values—which offeredworst performance
Figure 6. (A)Median and 95% confidence interval of the concordance index (c-index) across 500 bootstrap resamples, and (B) the
fraction of new information provided by the radiomics signature compared to the baseline clinicalmodel, which is equivalent to 1
minus the adequacy index (AI). Performance is reported for all 12models built with different feature set and assessmentmethod, with
the clinicalmodel included for reference. The best performingmodel is highlighted by a black box.
Figure 7.Hazard ratio heatmap for the radiomic features included in themodels produced by the personalised and 50%phase
selectionwith the assessmentmethods: none, averaging (3), and stability (3). A significant p-value (<0.05) is highlighted by a black box
around the relevant feature. Themost features are selected in the personalisedmodel.
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regardless of whethermean ormedian averagingwas used. Themost stable phasewas selected as 50% in 33%of
cases but varied across thewhole range. The bestmodel performancewas achievedwhen traditional stability
assessmentwas omitted, this stepwould remove features requiring sharp image detail that only occurs in one or
a few phases. In summary, a single stable 4Dphase led to bettermodel performance, likely because it represents
small anatomical details with a higher resolution, therefore features sensitive tomotion should not be omitted. A
data-driven approach to selecting the phase achieves superior results and could aidmulti-institutional studies
where different 4Dprotocols are adopted.
In allmodels, prognostic features for distant failure were found. In the personalisedmodel, TF ‘GLDM
dependence variance’was significant, with an increased risk of distant failure for a higher variance. PF ‘LDLGLE’
ofGLDM in the personalisedmodel was prognostic even after averaging across neighbour phases was
implemented. This feature detects high dependence groups of low intensity (Sun andWee 1983), and a higher
value leads to a protective effect (HR< 1). This feature was also included inmodels after stability assessment.
After stability assessment across neighbour phases, PF ‘Small DependenceHighGrey Level Emphasis’ ofGLDM
was a significant feature included in themodel, stating that small dependence groups of high intensity around
the tumour border offer increased risk.With no assessment, TF ‘GLCMmaximumprobability’was significant
formean,median, and 50%, a higher probability of themost commonGLCM leads toworse prognosis
(Haralick et al 1973).
More PFs thanTFs are included in the clinical-radiomicsmodels suggesting PFs aremore important for
distant failure prognosis. In summary, higher intensity groups outside the tumour bordermay lead toworse
prognosis. Out of clinical features, tumour lobe location is prognostic, with lower lobe tumours performing
worse, potentially related to overperfusion at the lung bases (Shaverdian et al 2017). Such conclusions are
hypothesis-generating until validation or larger sample size studies are performed. Overall, evidence is building
to suggest importance of the peritumoural region for distantmetastasis prediction fromboth pathology and
imaging studies (Shimada et al 2010, Kadota et al 2015,Dou et al 2018). Such a biomarker would improve
current clinical prediction as patient factors (i.e. stage, ECOGperformance status, and age) are not consistently
prognostic for distant failure (Loganadane et al 2016,Miller et al 2019).
To extract imaging biomarkers a single phase is preferable to averaging across all phases, as it can provide
useful information for features highly sensitive to respiratorymotion (Lafata et al 2018). In this work, we
establish that requiring stability across phases is highly detrimental in 4D-CT radiomics. This is in contrast to the
improved prognostic performance stability assessment has for FB-CT studies where there is largemotion
blurring impacting feature extraction (Du et al 2019). In this study, feature stability was dependent on tumour
motion (as also found by Tanaka et al 2019), and tumour volume. Alternativemeasures to stability assessment
could be tested such as identifying features sensitive to small shifts between the image andROImask to avoid
segmentation ‘style’ causing bias (Zwanenburg et al 2019a), and use of test-retest feature selection. To provide a
potential balance between robustness andmodel performancewe suggest to average phases around the phase
selected or only require stability across three phases, this reducedmodel performance butwas still preferable to
the 50%phase or averaging across all phases.
Themost stable phase for each patient wasmost often near exhale (40%–60%), followed by inhale peak
(0%). This is expected asmid-exhalation phases are typically the least stable; the tumourmoves fastest during
these phases resulting in the largest shape deviations compared to FB-CT (Rietzel et al 2006). Interestingly,mid-
phaseswere selected for a small proportion of patients, further supporting a data-driven approach for phase
selection as opposed to an assumption across the cohort. One possible explanation for this behaviour could be
cardiacmotion that is uncorrelatedwith respiratorymotion and can beminimal at any phase i.e. phase with the
leastmotion is not always exhale. Another explanation could be the phase-binning approach implemented, in
this study 50% is not always the true end-exhale unless patients have sinusoidal breathing. Alternatively, artifacts
occur in over 90%of 4D-CT images (Yamamoto et al 2008), and presence of artifacts reduce suitability of end-
exhale. All explanationsmake a data-driven approach favourable, to select the bestmethod to account for 4D
protocol, patients’ respiratory differences, and an individual tumours proximity to the heart.
Each 4Dphase uses less imaging dose in comparison to composite and FB-CT scans. A single phasemay
therefore displaymore heterogeneity than composite scans due to increased noise. Composite scans reduce
noise but also limit the visibility of small anatomical details. AIP features have been studied for distant failure
prediction (Huynh et al 2017), but results are inconclusive (Lafata et al 2018).We did not studyAIP as data is
blurred due to tumourmotion. An alternative is themotion compensated (mid-position) scan (Wolthaus et al
2008), which displays the tumour at an average positionwith reduced noise asmultiple phases are combined.
This seems favourable, but does require assessment in future work, as limitations in deformable registration
accuracy could still affect subtle details (Mercieca et al 2018).
Equally as important for future consideration, an automatedmethodwas used to generate aGTVon every
phase, allowing for large-scale analysis without the need formanual contouring. Thismethodology could
introduce small errors in the shape of the tumour, but it is validated toworkwell within the limits of observer
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variation and improve prognosticmodelling (Davey et al 2020a). However, the tumour border largely influences
radiomic features (Pavic et al 2018), and a potential limitation is that only a single segmentation techniquewas
tested. If themodel was intended for clinical purposes,multiple segmentations are required to obtain a better
radiomics quality score (Lambin et al 2017), and to incorporate uncertainty inmodelling or as a feature selection
stage. Additional considerations for a clinical studywould include resamplingmethods and bin discretisation.
Such tests have been omitted in this study to focus on the sole issue of optimising phase selection for 4D-CT
imaging biomarker studies. The segmentationmethod also assumes deformation of the tumour is small
compared to translationalmotion. Larue et al allowed for tumour deformationwhen comparing 4Dphases and
found 32%of tumour shape features are unstable across all phases (Larue et al 2017), however, this only
measures the opinion of one observer withmanual delineation on every phase. This is not feasible in larger
cohort studies, andwithoutmanual assessment it is difficult to distinguish between biological shape changes,
and that due to artifacts. Biomechnicalmodels that account for tumour deformation have been developed and
tested in small cohorts (Jafari et al 2021), and could aid extension of the segmentationmethodology in future.
Another limitation of traditional radiomics is that spatial information is collapsed to single feature values to
describe a region-of-interest. To incorporatemore informationwe tested twoROIs: the tumour and the
peritumour arbitrarily defined based onwork byDou et al (2018). The proposed bordermay not be optimum for
predicting distant failure, but the generated hypothesis can be used to investigate this further with novel
techniques thatmaintain spatial information (Davey et al 2020b).Well known to the radiomics community, the
ROI volume strongly influences feature values and is amajor confounder. In this studywe removed features with
correlation coefficient of greater than 0.5with tumour volume, this is an arbitrary threshold but correlation
assessment is commonwith oftenmore lenient thresholds implemented (Li et al 2017). In previous work, we
have noted evenweak correlations can have an impact on the apparent prognostic nature of radiomic features,
so potentially significant features would have to be explored further to assess clinical relevance (Davey et al
2020c). Of course, with any feature selection approach clinically relevant parameters can be lost (Leger et al
2017). Furthermore, small tumour volumesmay not be adequately sampled to extract all features.We ensured
all ROIswere above the size limit of 64 voxels (as implemented by LifeX,Nioche et al 2018), but this limit has not
been formally evidenced and further research is required to determinewhat threshold is suitable for different
features.
Amain limitation of our study is the sample size for analysis, but, this remains one of the larger sample size
SABR radiomic studies, as typically nomore than 170 patients are studied (Huynh et al 2017, Lafata et al 2019, Li
et al 2017, Oikonomou et al 2018). In addition, the internal validation implemented increases confidence in the
conclusions. To further increase confidence, we tested three supervised feature selection techniques following
advice of Leger et al (2017). After feature selection, we implemented a simple Cox regressionmodel. This has
been shown to perform just as well asmore complexmodels (i.e. boosted-Cox), and feature selection is the area
which ismore prone to error (Parmar et al 2015a, 2015b, Leger et al 2017).We selected the feature selection
method that had the best performance in cross-validationwhilstminimising difference between train and test,
whichwas theMRMRassessment. Alternativemethods to comparingmultiple feature selectionmethods exist:
such as assessing the stability (Parmar et al 2015a), or creating an ensemblemodel. Regardless of technique
implemented the conclusions remained the same, with optimal performance of the personalised approach.
As the gold-standard breath-holdCT is not standard of care, we have suggested amethod to obtain the single
phase of optimal quality for biomarker assessment (Scrivener et al 2016,Oliver et al 2017). The personalised
approach of selecting themost stable phasewill allow for prognostic information to be identifiedwhich is lost
with current approaches of either requiring stability assessment across all phases, or assuming the 50%phase
(exhale) is optimal. Although this framework has been evaluated in the context of traditional radiomics where
many features are tested, it is also useful to consider when testing a single imaging biomarker on 4D-CT. In this
study, we used all radiomic features to inform selection of optimal phase. To extend to a single biomarker study,
two approaches could be tested: selecting the optimal phase for the single feature or usingmotion-sensitive
comparison scores (e.g. difference in radiomic features) to determine themost stable phase.
5. Conclusion
Assessment of featuremotion stability is important for radiomic analysis on FB-CTdata, but reducesmodel
performance and removes prognostic features from the finalmodel when using a single phase from a 4Ddataset.
To increasemodel performance, extracting features from a single phase is preferable to averaging across all
phases. To select the single phase adopting our personalised approach is superior to assuming the 50%phase is
optimal for all patients. This remains the case when averaging themost stable and neighbour phase features to
reduce noise. Overall, we have set up a framework to perform radiomics analysis on 4D-CT and highlighted a
clinical hypothesis to take forward for validation and further study.
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